Xoma Shares Surge on Impressive Quarterly Earnings

Xoma Royalty Corporation delivered a powerful financial performance in the third quarter of 2025, significantly exceeding analyst forecasts with a GAAP earnings per share of $0.70. The biotechnology royalty aggregator also reported substantial progress in its strategic acquisition initiatives.

The company’s latest financials reveal a remarkable turnaround, posting a net income of $14.1 million compared to a loss during the same period last year. Quarterly cash receipts from licensing royalties and commercial payments reached $14.3 million, bringing the total cash collections to $43.9 million by the end of September.

Strategic investments in HilleVax and Turnstone generated significant returns, contributing $17.9 million and $1.8 million in gains respectively. Xoma has deployed $25.0 million year-to-date to expand its Read more...